✦ LIBER ✦

Costs of aredia® treatment in patients with malignant tumors, osteolytic bone disease, and pain

✍ Scribed by Gessner, U.; Thürlimann, B.; Horisberger, B.

Book ID: 121925427
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 152 KB
Volume: 17
Category: Article
ISSN: 8756-3282
DOI: 10.1016/8756-3282(96)88005-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pamidronate treatment in patients with m

Pamidronate treatment in patients with malignant osteolytic bone disease and pain

✍ D. Koeberle; L. Bacchus; B. Thuerlimann; H.-J. Senn 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 75 KB

Economic analysis of terminal care for p

Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate

✍ U. Gessner; D. Koeberle; B. Thuerlimann; L. Bacchus; B. Horisberger 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 105 KB

Pamidronate for pain control in patients

Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study

✍ B. Thürlimann; R. Morant; W. F. Jungi; A. Radziwill 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 495 KB

In a prospective dose-escalation study tolerability and effectiveness of repeated infusions with intravenous pamidronate were investigated. A total of 80 patients with proven malignancy and pain due to osteolytic bone disease were enrolled. Doses of 30 mg, 45 mg, 60 mg and 90 mg pamidronate, given e

Procollagen type I N-propeptide is a pre

Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates

✍ M. Joerger; A. Templeton; D. Köberle; H. Engler; W. F. Riesen; B. Thürlimann 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 404 KB

PATHOGENESIS AND TREATMENT OF ALTERED BL

PATHOGENESIS AND TREATMENT OF ALTERED BLOOD COAGULABILITY IN PATIENTS WITH MALIGNANT TUMORS

✍ Clarence Merskey 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB

The clinical use of bone resorption mark

The clinical use of bone resorption markers in patients with malignant bone disease

✍ Robert E. Coleman 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 1 views

## Abstract ## BACKGROUND Advanced tumors often metastasize to bone, resulting in a variety of skeletal complications. Bisphosphonates are potent inhibitors of osteoclast‐mediated bone resorption that reduce the incidence and delay the onset of skeletal complications and reduce the need for radiat